Compare COFS & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | COFS | LXEO |
|---|---|---|
| Founded | 1898 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.9M | 396.5M |
| IPO Year | 1995 | 2023 |
| Metric | COFS | LXEO |
|---|---|---|
| Price | $34.15 | $4.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $34.00 | $18.44 |
| AVG Volume (30 Days) | 106.1K | ★ 962.4K |
| Earning Date | 04-24-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $227,624,000.00 | $654,000.00 |
| Revenue This Year | $22.13 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $37.30 | ★ N/A |
| Revenue Growth | ★ 63.64 | N/A |
| 52 Week Low | $26.10 | $3.60 |
| 52 Week High | $34.90 | $10.99 |
| Indicator | COFS | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 57.82 | 47.34 |
| Support Level | $29.98 | $4.27 |
| Resistance Level | $34.90 | $5.36 |
| Average True Range (ATR) | 0.98 | 0.35 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 63.18 | 30.48 |
ChoiceOne Financial Services Inc is a full-service banking institution. It is engaged in the business of providing personal and business banking solutions, borrowing solutions, and treasury notes and bonds services. The bank's product and services portfolio consist of time, savings and demand deposits, safe deposit services, automated transaction machine services, commercial and consumer loans, commercial lending to business, industry, agricultural, construction, inventory, and real estate categories. Its primary market area is Kent, Muskegon, Newaygo, and Ottawa counties in western Michigan, and Lapeer, Macomb, and St. Clair counties in southeastern Michigan in the communities where the Bank's respective offices are located.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.